| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Medical Sciences, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [K. L., M. G. B., J. R. T., G. D. K.], and Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts 02129 [D. W. B.]
Multidrug resistance-associated protein (MRP) and canalicular multispecific organic anion transporter (cMOAT) are closely related mammalian ATP-binding cassette transporters that export organic anions from cells. Transfection studies have established that MRP confers resistance to natural product cytotoxic agents, and recent evidence suggests the possibility that cMOAT may contribute to cytotoxic drug resistance as well. Based upon the potential importance of these transporters in clinical drug resistance and their important physiological roles in the export of the amphiphilic products of phase I and phase II metabolism, we sought to identify other MRP-related transporters. Using a degenerate PCR approach, we isolated a cDNA that encodes a novel ATP-binding cassette transporter, which we designated MOAT-B. The MOAT-B gene was mapped using fluorescence in situ hybridization to chromosome band 13q32. Comparison of the MOAT-B predicted protein with other transporters revealed that it is most closely related to MRP, cMOAT, and the yeast organic anion transporter YCF1. Although MOAT-B is closely related to these transporters, it is distinguished by the absence of a 
200 amino acid NH2-terminal hydrophobic extension that is present in MRP and cMOAT and which is predicted to encode several transmembrane spanning segments. In addition, the MOAT-B tissue distribution is distinct from MRP and cMOAT. In contrast to MRP, which is widely expressed in tissues, including liver, and cMOAT, the expression of which is largely restricted to liver, the MOAT-B transcript is widely expressed, with particularly high levels in prostate, but is barely detectable in liver. These data indicate that MOAT-B is a ubiquitously expressed transporter that is closely related to MRP and cMOAT and raise the possibility that it may be an organic anion pump relevant to cellular detoxification.
1 This work was supported by NIH Grant CA63173 and American Cancer Society Grant DHP-131 (to G. D. K.), NIH Grant CA06927 to Fox Chase Cancer Center, and by an appropriation from the Commonwealth of Pennsylvania.
2 To whom requests for reprints should be addressed, at Fox Chase Cancer Center, 7701 Burholme Ave., Philadelphia, PA 19111. Phone: (215) 728-5317; Fax: (215) 728-3603.
Received 3/ 3/98. Accepted 5/15/98.
This article has been cited by other articles:
|
|
 |
|
  M. G. Belinsky, P. Guo, K. Lee, F. Zhou, E. Kotova, A. Grinberg, H. Westphal, I. Shchaveleva, A. Klein-Szanto, J. M. Gallo, et al. Multidrug Resistance Protein 4 Protects Bone Marrow, Thymus, Spleen, and Intestine from Nucleotide Analogue-Induced Damage Cancer Res., January 1, 2007; 67(1): 262 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Zamek-Gliszczynski, K.-i. Nezasa, X. Tian, A. S. Bridges, K. Lee, M. G. Belinsky, G. D. Kruh, and K. L. R. Brouwer Evaluation of the Role of Multidrug Resistance-Associated Protein (Mrp) 3 and Mrp4 in Hepatic Basolateral Excretion of Sulfate and Glucuronide Metabolites of Acetaminophen, 4-Methylumbelliferone, and Harmol in Abcc3-/- and Abcc4-/- Mice J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1485 - 1491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Deeley, C. Westlake, and S. P. C. Cole Transmembrane Transport of Endo- and Xenobiotics by Mammalian ATP-Binding Cassette Multidrug Resistance Proteins. Physiol Rev, July 1, 2006; 86(3): 849 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Dallas, D. S. Miller, and R. Bendayan Multidrug resistance-associated proteins: expression and function in the central nervous system. Pharmacol. Rev., June 1, 2006; 58(2): 140 - 161. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Couture, J. A. Nash, and J. Turgeon The ATP-Binding Cassette Transporters and Their Implication in Drug Disposition: A Special Look at the Heart. Pharmacol. Rev., June 1, 2006; 58(2): 244 - 258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Obligacion, M. Murray, and I. Ramzan Drug-Metabolizing Enzymes and Transporters: Expression in the Human Prostate and Roles in Prostate Drug Disposition J Androl, March 1, 2006; 27(2): 138 - 150. [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Norris, J. Smith, K. Tanabe, P. Tobin, C. Flemming, G. L. Scheffer, P. Wielinga, S. L. Cohn, W. B. London, G. M. Marshall, et al. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro Mol. Cancer Ther., April 1, 2005; 4(4): 547 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Brone and J. Eggermont PDZ proteins retain and regulate membrane transporters in polarized epithelial cell membranes Am J Physiol Cell Physiol, January 1, 2005; 288(1): C20 - C29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Jedlitschky, K. Tirschmann, L. E. Lubenow, H. K. Nieuwenhuis, J. W. N. Akkerman, A. Greinacher, and H. K. Kroemer The nucleotide transporter MRP4 (ABCC4) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage Blood, December 1, 2004; 104(12): 3603 - 3610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. E. Sauna, K. Nandigama, and S. V. Ambudkar Multidrug Resistance Protein 4 (ABCC4)-mediated ATP Hydrolysis: EFFECT OF TRANSPORT SUBSTRATES AND CHARACTERIZATION OF THE POST-HYDROLYSIS TRANSITION STATE J. Biol. Chem., November 19, 2004; 279(47): 48855 - 48864. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dallas, L. Schlichter, and R. Bendayan Multidrug Resistance Protein (MRP) 4- and MRP 5-Mediated Efflux of 9-(2-Phosphonylmethoxyethyl)adenine by Microglia J. Pharmacol. Exp. Ther., June 1, 2004; 309(3): 1221 - 1229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. E. Sauna, X.-H. Peng, K. Nandigama, S. Tekle, and S. V. Ambudkar The Molecular Basis of the Action of Disulfiram as a Modulator of the Multidrug Resistance-Linked ATP Binding Cassette Transporters MDR1 (ABCB1) and MRP1 (ABCC1) Mol. Pharmacol., March 1, 2004; 65(3): 675 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Lockhart, R. G. Tirona, and R. B. Kim Pharmacogenetics of ATP-binding Cassette Transporters in Cancer and Chemotherapy Mol. Cancer Ther., July 1, 2003; 2(7): 685 - 698. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yang, Q. Chen, and J.-T. Zhang Structural and Functional Consequences of Mutating Cysteine Residues in the Amino Terminus of Human Multidrug Resistance-associated Protein 1 J. Biol. Chem., November 8, 2002; 277(46): 44268 - 44277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. P. Lin, D. R. Johnson, R. A. Finch, M. G. Belinsky, G. D. Kruh, and A. C. Sartorelli Comparative Study of the Importance of Multidrug Resistance-associated Protein 1 and P-Glycoprotein to Drug Sensitivity in Immortalized Mouse Embryonic Fibroblasts Mol. Cancer Ther., October 1, 2002; 1(12): 1105 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-S. Chen, K. Lee, S. Walther, R. B. Raftogianis, M. Kuwano, H. Zeng, and G. D. Kruh Analysis of Methotrexate and Folate Transport by Multidrug Resistance Protein 4 (ABCC4): MRP4 Is a Component of the Methotrexate Efflux System Cancer Res., June 1, 2002; 62(11): 3144 - 3150. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Z. Khokhar, Y. She, V. W. Rusch, and F. M. Sirotnak Experimental Therapeutics with a New 10-Deazaaminopterin in Human Mesothelioma: Further Improving Efficacy through Structural Design, Pharmacologic Modulation at the Level of MRP ATPases, and Combined Therapy with Platinums Clin. Cancer Res., October 1, 2001; 7(10): 3199 - 3205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Lee, A. J. P. Klein-Szanto, and G. D. Kruh Analysis of the MRP4 Drug Resistance Profile in Transfected NIH3T3 Cells J Natl Cancer Inst, December 6, 2000; 92(23): 1934 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Sagara and M. Katoh Mitomycin C Resistance Induced by TCF-3 Overexpression in Gastric Cancer Cell Line MKN28 Is Associated with DT-diaphorase Down-Regulation Cancer Res., November 1, 2000; 60(21): 5959 - 5962. [Abstract] [Full Text]
|
|
|
|
|
|
H. Zeng, G. Liu, P. A. Rea, and G. D. Kruh Transport of Amphipathic Anions by Human Multidrug Resistance Protein 3 Cancer Res., September 1, 2000; 60(17): 4779 - 4784. [Abstract] [Full Text]
|
|
|
|
|
|
F. M. Sirotnak, H. G. Wendel, W. G. B. Bornmann, W. P. Tong, V. A. Miller, H. I. Scher, and M. G. Kris Co-administration of Probenecid, an Inhibitor of a cMOAT/MRP- like Plasma Membrane ATPase, Greatly Enhanced the Efficacy of a New 10-Deazaaminopterin against Human Solid Tumors in Vivo Clin. Cancer Res., September 1, 2000; 6(9): 3705 - 3712. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. A. M. H. Van Aubel, R. Masereeuw, and F. G. M. Russel Molecular pharmacology of renal organic anion transporters Am J Physiol Renal Physiol, August 1, 2000; 279(2): F216 - F232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gao, H.-R. Cui, D. W. Loe, C. E. Grant, K. C. Almquist, S. P. C. Cole, and R. G. Deeley Comparison of the Functional Characteristics of the Nucleotide Binding Domains of Multidrug Resistance Protein 1 J. Biol. Chem., April 21, 2000; 275(17): 13098 - 13108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Litman, M Brangi, E Hudson, P Fetsch, A Abati, D. Ross, K Miyake, J. Resau, and S. Bates The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2) J. Cell Sci., January 6, 2000; 113(11): 2011 - 2021. [Abstract] [PDF]
|
|
|
|
|
|
H. Zeng, L. J. Bain, M. G. Belinsky, and G. D. Kruh Expression of Multidrug Resistance Protein-3 (Multispecific Organic Anion Transporter-D) in Human Embryonic Kidney 293 Cells Confers Resistance to Anticancer Agents Cancer Res., December 1, 1999; 59(23): 5964 - 5967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Jariyawat, T. Sekine, M. Takeda, N. Apiwattanakul, Y. Kanai, S. Sophasan, and H. Endou The Interaction and Transport of beta -Lactam Antibiotics with the Cloned Rat Renal Organic Anion Transporter 1 J. Pharmacol. Exp. Ther., August 1, 1999; 290(2): 672 - 677. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Kool, M. van der Linden, M. de Haas, G. L. Scheffer, J. M. L. de Vree, A. J. Smith, G. Jansen, G. J. Peters, N. Ponne, R. J. Scheper, et al. MRP3, an organic anion transporter able to transport anti-cancer drugs PNAS, June 8, 1999; 96(12): 6914 - 6919. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Kruh and M. G. Belinsky RESPONSE: Re: Characterization of MOAT-C and MOAT-D, New Members' of the MRP/cMOAT Subfamily of Transporter Proteins J Natl Cancer Inst, May 19, 1999; 91(10): 888a - 889a. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Perkins, Y. A. Riojas, T. W. Wu, and S. M. Le Blancq CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages PNAS, May 11, 1999; 96(10): 5734 - 5739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. C. Young, B. G. Campling, T. Voskoglou-Nomikos, S. P. C. Cole, R. G. Deeley, and J. H. Gerlach Expression of Multidrug Resistance Protein-related Genes in Lung Cancer: Correlation with Drug Response Clin. Cancer Res., March 1, 1999; 5(3): 673 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-S. Chen, K. Lee, and G. D. Kruh Transport of Cyclic Nucleotides and Estradiol 17-beta -D-Glucuronide by Multidrug Resistance Protein 4. RESISTANCE TO 6-MERCAPTOPURINE AND 6-THIOGUANINE J. Biol. Chem., August 31, 2001; 276(36): 33747 - 33754. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
